ESPR - Esperion - taking on the Statin market

Investment Analysis Clubs Where Angels Fear to Tread
201

I realize this thread has gotten long.

So here is a summary:

  • CLEAR Outcomes Trial (2023–2024)

    • Mar 2023: Topline results — 13% MACE-4 reduction.

    • Late 2023: Full data presented.

    • Mar 2024: U.S. label update — CV risk reduction.

    • Aug 2025: ESC/EAS Level 1a recommendation.

  • Commercial Progress (U.S.)

    • 2020: Initial launch (LDL-C only).

    • 2024–2025: Post-label growth +42% H1 2025 prescriptions.

    • Payer access: >90% commercial, >80% Medicare.

    • Dec 2025: ACC PAD/Diabetes statement — first-line for LDL-C + limb benefits.

  • Global Expansion & Tech Transfer

    • Europe (Daiichi Sankyo): NILEMDO/NUSTENDI since 2020; Jan 2024 tech transfer announced — DSE assumes manufacturing responsibility (reduces Esperion COGS long-term).

    • Japan (Otsuka): Nov 2025 launch + $90M milestone; future manufacturing transition expected (similar cost relief).

    • Inventory build: Q3 2025 ~$108M net (up from $94M YE2024) — proactive scaling for U.S. demand + partner supply agreements; expected drawdown post-transfers (lower COGS 2027+).

  • Cost Optimizations / OpEx

    • OpEx trajectory: ~$160M annual run-rate 2024–2025; assumption cap $300M total (SG&A + R&D + COGS) from 2026 (breakeven inflection).

    • Tech transfers (Europe 2024, Japan future): Shift manufacturing burden to partners → COGS reduction ~$20–40M/year long-term.

    • Inventory management: Build for growth/partner bulk sales; post-transfer → lower carrying costs, improved margins.

  • IP / Exclusivity

    • ANDA settlements 2025: Generics barred to April 2040.

    • Alkem litigation ongoing.

    • Japan patent granted 2025: Triple combo protection.

  • Debt / Balance Sheet

    • June 2024: $304.7M OMERS DSE royalty sale.

    • Dec 2024: $150M Athyrium loan + $100M 2030 converts.

    • Nov 2025: $55M 2025 notes paid off.

    • Current debt: $250M.

    • Cash ~$197M; runway 2027+.

  • Dilution Summary

    • Shares basic: ~118M YE2023 → ~195M YE2024 → ~205M Q3 2025.

    • Major: Jan 2024 30M offering; Oct 2025 30M shares ($70M net).

    • Fully diluted: ~275M (warrants 26M @ $1.55, 2030 converts 32M, options/RSUs ~17M).

    • Forward expectation: Minimal new dilution post-2026 (FCF covers ops); potential warrant exercises cash-accretive.

  • Investor Communications (Outside Quarterly ERs)

    • Apr 2025: R&D Day (pipeline focus, ESP-2001 nomination).

    • Jan 2025: JP Morgan Healthcare Conference presentation.

    • Nov 2025: Jefferies London Healthcare Conference (CFO remarks on debt payoff).

    • Regular: Firesides at Cowen, Cantor, Needham (2024–2025 dates scattered Q1–Q3).

  • Bempedoic Acid Additional Data

    • 2022: Preclinical ADPKD cyst inhibition.

    • 2025: AHA — VTE/monotherapy subsets.

    • Dec 2025: ACC PAD limb benefits.

  • Next-Gen ACLY Pipeline

    • Apr 2025: R&D Day — ESP-2001 PSC nomination.

    • Oct 2025: IND-enabling PSC; goal IND 2026.

    • Kidney: Preclinical 2022 + Phase 2 completed; BEAT-PKD (DoD) not yet recruiting.

    • Oncology: No direct activity (Espervita separate).

  • Current Snapshot (Dec 19, 2025)

    • Market cap ~$900M.

    • Breakeven 2026 trajectory.

    • Triple combo development ongoing.

5 Likes
202

unsurprisingly, I didn’t do a bunch of work on my Esperion outline during my holiday breaks. go figure.

Ah well…stress reduced, so there’s that.

In the news today though:
https://www.esperion.com/news-releases/news-release-details/esperion-participate-upcoming-44th-annual-jp-morgan-healthcare

2 Likes
203

PR and early ER preliminary results issued prior to JPM health conf this Wed.

https://www.esperion.com/news-releases/news-release-details/esperion-provides-business-update-44th-annual-jp-morgan

AI/Grok take:

My take on the January 11, 2026 J.P. Morgan update (no fluff, just opinion based on everything in our conversation):

This is the strongest, cleanest update Esperion has given in years. It’s not hype; it’s a credible pivot from “survive and grow U.S. sales” to “become a multi-blockbuster global company by 2040.”

Positive takeaways (very bullish):

• Preliminary 2025 U.S. sales $156–160M (+35–38% YoY) is solid execution on the back of the label expansion — better than many expected after the dilution fears.

• Total revenue $400–408M (+55–59% ex-milestones) shows the global royalty engine is kicking in even before DSE fully reverts.

• Cash at ~$168M year-end is higher than I thought — runway comfortably into 2027 without raising, which kills a big overhang.

• 2026 OpEx guidance $210–245M is aggressive cost control (down from ~$260M run-rate) — proves they can hit breakeven/FCF positive in 2026 while still funding pipeline.

• Vision 2040 reveal is real strategy, not fluff. Naming rare hepatic (PSC) and renal as focus areas + multi-product goal signals they see ACLY as a platform, not a single-asset story.

• Q4 scripts +34% Y/Y and +11.3% Q/Q is the best quarterly growth we’ve seen — momentum is real heading into guidelines.

Concerns / realism check:

• $210–245M OpEx still eats a lot of the early FCF — profitability will be modest in 2026–2027 unless U.S. accelerates faster than 35–40%.

• Vision 2040 is 14 years away — investors want near-term catalysts (guidelines Q1 2026, triple combo progress, early PSC data).

• Merck’s oral PCSK9 is still a threat on lipids approval in 2026–2027, even if outcomes are delayed.

Overall opinion:

This is the first PR in a long time that makes $ESPR feel like a real growth story again, not just a “surviving biotech.”

The combination of strong 2025 numbers, clear cost discipline, higher cash, and a credible long-term platform vision makes the $900M–$1B market cap look absurdly cheap if execution continues.

I now see $15–20/share by end of 2026 as realistic (not optimistic), assuming guidelines hit and Q1–Q2 2026 scripts stay strong.

The stock is still priced like it’s only worth the U.S. BA franchise — ignoring the royalty reversion, cash build, and ACLY pipeline entirely. That’s the mispricing.

If they deliver on Vision 2040 roadmap without major stumbles, this thing has 10×+ potential by 2030.

Dreamer

3 Likes
204

Down 8.5% today. I added to my position, 20%. Now 3% of IRA, plus a bigger part of my brokerage account. I expect a broader market decline so have to close my eyes and focus on “the other side”, ‘cause if I am right ESPR won’t be pretty in risk-off season.

KC

2 Likes
205

Hey KC!

I get it, but i think turnarounds, under-the-radar, or acquisition targets, can more easily defy macro.

Esperion script growth (US only)

• Q3 2024: +12%
• Q4 2024: +12%
• Q1 2025: +2%
• Q2 2025: +10%
• Q3 2025: +9%
• Q4 2025: +11.3%

Basically averaged 9%+ q/q script growth since label change.

  1. ANDA (patent() finality seems near
  2. Guideline updates seem near
  3. Tech transfer/profitability seems near
  4. DSE ramping
  5. Otsuka ramping
  6. RoW still emerging

Given their royalty sale agreement looks like debt on the books, and their OpEx looks worse now than it will be due to tech transfer w DSE, i think their profitability this year will take most by surprise.

The more victories on patent front, the more valuable they are in a buyout and the longer they make peak profits 2028 and onward.

Expect stock price games in short term.

If guideline updates in Q1 favor bempedoic acid, this investment is derisked further.

Best to you,
Dreamer

2 Likes
206

Latest investor deck

https://www.esperion.com/static-files/48226938-a34f-41e8-9130-e2e5d819df0c

2 Likes
207

Read through the transcript.. most interesting from my perspective were..

  1. Sheldon commented multiple times that no further dilution is expected or needed. I feel like we have heard that story before but maybe he means it this time.
  2. talked multiple times about making small/immediately accretive acquisitions to position for 2040. Its a long runway so we will see how that plays out.
  3. sales in Japan.. really.. really good.
  4. total revenue excluding all milestone payments growing at greater than 60%/year.

Maybe people are worried about Merck a bit but seems like a reasonable risk and this is a franchise that should be printing money over the next couple of years

3 Likes
208

Seems market knee jerk reaction is to not agree with the long term strategy. Giving back market cap in excess of upfront cash paid.

So… why not stay focused on getting good at marketing your main drug, hmmm. I’m certainly bringing my bias of wanting to get acquired rather than being an acquirer.

Brief AI summary -

Key Deal Details

Esperion Therapeutics agreed to acquire Corstasis Therapeutics, a privately held biopharma company.

The deal includes:

  • $75 million upfront cash paid by Esperion.

  • Up to $180 million in milestone payments tied to regulatory and commercial targets.

  • Low double-digit royalties on future sales of products acquired.

  • Corstasis will become a wholly owned subsidiary upon closing.

  • The acquisition is expected to close in Q2 2026 subject to customary conditions.

Strategic Rationale

  • The main asset Esperion is gaining is Enbumyst™ (bumetanide nasal spray) — the first and only FDA-approved intranasal loop diuretic for treating edema associated with congestive heart failure (CHF) and certain hepatic and renal diseases in adults.
  • Enbumyst’s novel nasal delivery offers a more convenient outpatient option compared with traditional oral or IV diuretics.
  • Esperion plans to leverage its existing commercial infrastructure to expand its cardiovascular portfolio and drive growth, aiming at a U.S. market opportunity potentially exceeding several billion dollars.

Strategic Context

  • The acquisition supports Esperion’s broader strategy to build multiple revenue streams beyond its current cholesterol-lowering products and strengthen its presence in heart failure and fluid management therapies.
  • Company leadership highlighted Enbumyst as a clinically meaningful innovation that could improve patient outcomes and reduce hospitalizations.

Strategic Fit in Long-Term Plan

  • Diversifies beyond LDL-C drugs: Until now, Esperion’s revenue has largely come from its cholesterol-lowering therapies (like bempedoic acid products). Adding Enbumyst, an outpatient edema therapy, expands its cardiovascular portfolio into a new therapeutic area that complements its existing commercial infrastructure.
  • Supports Vision 2040: Management frames the deal as part of its Vision 2040, a long-range strategy to deliver differentiated cardiovascular and related disease treatments for high-need patients. Enbumyst’s novel nasal delivery and market position align with that vision and could help drive sustained growth and broaden patient reach.
  • Revenue growth & market expansion: Enbumyst targets a large U.S. population with congestive heart failure and edema, potentially creating a new multi-billion-dollar revenue stream alongside their existing products, strengthening long-term financial prospects.
  • Builds on commercial strengths: The acquisition leverages Esperion’s existing sales and marketing organization, potentially accelerating adoption of Enbumyst and enhancing overall franchise value.
  • Pipeline extension: Corstasis also has additional assets (like a subcutaneous injector in development), offering further optionality for future growth beyond the initial nasal spray product.

In short, the deal isn’t just an add-on product purchase — it’s a strategic step toward broadening Esperion’s therapeutic scope, strengthening revenue diversity, and supporting growth goals under its long-term Vision 2040 framework.

2 Likes
209

Yeah…good summary.

Busy w work, so may comment later.

Guidelines for bempedoic acid may drop any day this month, so may be better to wait and see what that looks like and reframe the entire investment.

After guidelines, the biggest catalyst still remains of patent extension, and the final ANDA cases may be settled this year. That is a game changer.

After that…it is just sales execution and maybe partnership deals.

Dreamer